Literature DB >> 22215891

New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation.

Jack Ansell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22215891     DOI： 10.1161/CIRCULATIONAHA.111.031153

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  19 in total

1.  MEDEX South Carolina: a progress report.

Authors:  K J Buhmeyer; A R Hutson
Journal:  J S C Med Assoc       Date:  1975-11

Review 2.  The new oral anticoagulants: results of clinical trials and practical applications.

Authors:  Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

Review 3.  Anticoagulants in atrial fibrillation patients with chronic kidney disease.

Authors:  Robert G Hart; John W Eikelboom; Alistair J Ingram; Charles A Herzog
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

4.  Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting.

Authors:  Shin-Yu Lee; Roy Cherian; Irene Ly; Claire Horton; Alaya Levi Salley; Urmimala Sarkar
Journal:  Jt Comm J Qual Patient Saf       Date:  2017-04-20

5.  Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.

Authors:  Alvaro Alonso; Lindsay G S Bengtson; Richard F MacLehose; Pamela L Lutsey; Lin Y Chen; Kamakshi Lakshminarayan
Journal:  Stroke       Date:  2014-07-03       Impact factor: 7.914

Review 6.  Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Natalie J Carter; Greg L Plosker
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

Review 7.  Target specific oral anticoagulants in the management of thromboembolic disease in the elderly.

Authors:  Surekha Maddula; Jack Ansell
Journal:  J Thromb Thrombolysis       Date:  2013-08       Impact factor: 2.300

8.  Risk of long-term anticoagulation under sustained severe arterial hypertension: A translational study comparing warfarin and the new oral anticoagulant apixaban.

Authors:  Waltraud Pfeilschifter; Thurid Steinstraesser; Patrick Paulus; Pia Susan Zeiner; Ferdinand Bohmann; Alf Theisen; Edelgard Lindhoff-Last; Cornelia Penski; Marlies Wagner; Michel Mittelbronn; Christian Foerch
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

9.  Predictors of Thromboembolic Events in Patients with Ventricular Assist Device.

Authors:  Amelia K Boehme; Salpy V Pamboukian; James F George; Chrisly Dillon; Emily B Levitan; Russell Griffin; T Mark Beasley; Gerald McGwin; James K Kirklin; Nita A Limdi
Journal:  ASAIO J       Date:  2015 Nov-Dec       Impact factor: 2.872

10.  Clinical and Radiological Characteristics of Vitamin K Versus Non-Vitamin K Antagonist Oral Anticoagulation-Related Intracerebral Hemorrhage.

Authors:  Małgorzata M Miller; Jessica Lowe; Muhib Khan; Muhammad U Azeem; Susanne Muehlschlegel; Adalia H Jun-O'Connell; Richard P Goddeau; Majaz Moonis; Danielle Gritters; Brian Silver; Nils Henninger
Journal:  Neurocrit Care       Date:  2019-08       Impact factor: 3.210
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.